Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Atossa Therapeutics

24/02/2023 11:01

* Atossa Therapeutics Inc  ATOS.OQ   ATOS.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Atossa Therapeutics
Inc
is for a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atossa
Therapeutics Inc is $5​, above​ its last closing price of $0.74.
​​​

This summary was machine generated February 24 at 11:01 GMT. 
All figures in US dollars  unless otherwise stated